PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer
Journal of Clinical Oncology · 10.06.2024 · 42 (17) · 2050-2060
DOI: 10.1200/jco.23.01940 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.06.2024. Verfasst von Erica L Mayer und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Breast Neoplasms, Pyridines, Piperazines, Aromatase Inhibitors. Die Arbeit wurde bisher 138-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6is) are an important component of treatment for hormone receptor–positive/human epidermal growth factor receptor 2–negative (HER2–) metastatic breast cancer (MBC), but it is not known if patients might derive benefit from continuation of CDK4/6i with endocrine therapy beyond initial tumor progression or if the addition of checkpoint inhibitor therapy has value in this setting. METHODS The randomized multicenter phase II PACE trial enrolled patients with hormone receptor–positive/HER2– MBC whose disease had progressed on previous CDK4/6i and aromatase inhibitor (AI) therapy. Patients were randomly assigned 1:2:1 to receive fulvestrant (F), fulvestrant plus palbociclib (F + P), or fulvestrant plus palbociclib and avelumab (F + P + A). The primary end point was investigator-assessed progression-free survival (PFS) in patients treated with F versus F + P. RESULTS Overall, 220 patients were randomly assigned between September 2017 and February 2022. The median age was 57 years (range, 25-83 years). Most patients were postmenopausal (80.9%), and 40% were originally diagnosed with de novo MBC. Palbociclib was the most common previous CDK4/6i (90.9%). The median PFS was 4.8 months on F and 4.6 months on F + P (hazard ratio [HR], 1.11 [90% CI, 0.79 to 1.55]; P = .62). The median PFS on F + P + A was 8.1 months (HR v F, 0.75 [90% CI, 0.50 to 1.12]; P = .23). The difference in PFS with F + P and F + P + A versus F was greater among patients with baseline ESR1 and PIK3CA alterations. CONCLUSION The addition of palbociclib to fulvestrant did not improve PFS versus fulvestrant alone among patients with hormone receptor–positive/HER2– MBC whose disease had progressed on a previous CDK4/6i plus AI. The increased PFS seen with the addition of avelumab warrants further investigation in this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
- Harvard Medical School, Boston, MA.
- Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
- Department of Medical Oncology, Miami Cancer Institute, Miami, FL.
- Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO.
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
ORCID-Profile: Erica L Mayer, Nikhil Wagle, Reshma Mahtani, Cynthia Ma, Angela DeMichele, Massimo Cristofanilli, Kathy D Miller, Yara Abdou, Priyanka Sharma, Sonya Reid, Naomi Ko, Ann H Partridge, Wendy Y Chen, Jillian Alberti, Eric Gauthier, Harold J Burstein, Meredith M Regan, Sara M Tolaney
Förderung
- NCI NIH HHS
Zitieren
APA
Mayer, E. L., Ren, Y., Wagle, N., Mahtani, R., Ma, C., DeMichele, A., Cristofanilli, M., Meisel, J., Miller, K. D., Abdou, Y., Riley, E. C., Qamar, R., Sharma, P., Reid, S., Sinclair, N., Faggen, M., Block, C. C., Ko, N., Partridge, A. H., …, & Tolaney, S. M. (2024). PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer. Journal of Clinical Oncology, 42(17), 2050-2060. https://doi.org/10.1200/jco.23.01940
Vancouver
Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C, DeMichele A, et al. PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer. Journal of Clinical Oncology. 2024;42(17):2050-2060. doi:10.1200/jco.23.01940
BibTeX
@article{Mayer2024,
author = {Mayer, Erica L and Ren, Yue and Wagle, Nikhil and Mahtani, Reshma and Ma, Cynthia and DeMichele, Angela and Cristofanilli, Massimo and Meisel, Jane and Miller, Kathy D and Abdou, Yara and Riley, Elizabeth C and Qamar, Rubina and Sharma, Priyanka and Reid, Sonya and Sinclair, Natalie and Faggen, Meredith and Block, Caroline C and Ko, Naomi and Partridge, Ann H and Chen, Wendy Y and DeMeo, Michelle and Attaya, Victoria and Okpoebo, Amanda and Alberti, Jillian and Liu, Yuan and Gauthier, Eric and Burstein, Harold J and Regan, Meredith M and Tolaney, Sara M},
title = {PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {17},
pages = {2050--2060},
doi = {10.1200/jco.23.01940}
}
EUVIMED